TY - JOUR
T1 - New evidence on the management of Lewy body dementia
AU - Taylor, John Paul
AU - McKeith, Ian G.
AU - Burn, David J.
AU - Boeve, Brad F.
AU - Weintraub, Daniel
AU - Bamford, Claire
AU - Allan, Louise M.
AU - Thomas, Alan J.
AU - O'Brien, John T.
N1 - Funding Information:
The two systematic reviews informing this Review 14,18 and the Delphi process were funded as part of a UK NIHR programme grant for applied research entitled Improving the diagnosis and management of Lewy body dementia (DIAMOND-Lewy; grant reference number DTC-RP-PG-0311-12001). This evidence presented in this Review informed our development of formal Lewy body dementia management guidelines and toolkits as part of the Diamond Lewy research programme. These clinical guidelines were developed for clinical practice in the UK and based on UK drug availability, but adaptable for other countries. We also acknowledge infrastructure support provided by Newcastle Biomedical Research Centre hosted by Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation Trust and Newcastle University, the Cambridge Biomedical Research Centre hosted by the Cambridge University Hospitals NHS Foundation Trust and the Cambridgeshire and Peterborough NHS Foundation Trust, and the Cambridge Centre for Parkinson-Plus within the University of Cambridge. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/2
Y1 - 2020/2
N2 - Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish. Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia. Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia. However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.
AB - Dementia with Lewy bodies and Parkinson's disease dementia, jointly known as Lewy body dementia, are common neurodegenerative conditions. Patients with Lewy body dementia present with a wide range of cognitive, neuropsychiatric, sleep, motor, and autonomic symptoms. Presentation varies between patients and can vary over time within an individual. Treatments can address one symptom but worsen another, which makes disease management difficult. Symptoms are often managed in isolation and by different specialists, which makes high-quality care difficult to accomplish. Clinical trials and meta-analyses now provide an evidence base for the treatment of cognitive, neuropsychiatric, and motor symptoms in patients with Lewy body dementia. Furthermore, consensus opinion from experts supports the application of treatments for related conditions, such as Parkinson's disease, for the management of common symptoms (eg, autonomic dysfunction) in patients with Lewy body dementia. However, evidence gaps remain and future clinical trials need to focus on the treatment of symptoms specific to patients with Lewy body dementia.
UR - http://www.scopus.com/inward/record.url?scp=85078506717&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078506717&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(19)30153-X
DO - 10.1016/S1474-4422(19)30153-X
M3 - Review article
C2 - 31519472
AN - SCOPUS:85078506717
SN - 1474-4422
VL - 19
SP - 157
EP - 169
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 2
ER -